Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of the biggest challenges in biotech.
Read MoreIn this thought-provoking episode of Biotech 2050, host Alok Tayi sits down with Liam Killingstad, Member at Finiam Investments, to unpack the growing influence of family offices in biotech. Driven by his own family's experience with rare cancers, Liam shares how that journey sparked Finiam's deep dive into biotech investing and the co-creation of companies like Khora Therapeutics.
Read MoreHost Alok Tayi sits down with Clare Terlouw, Head of Ventures at LifeArc Ventures, to explore biotech investing from an LP perspective. Clare shares her unique journey—from physiotherapy to investment banking and, ultimately, leading venture investments at a medical charity. The conversation delves into LifeArc’s role in bridging the funding gap for biotech innovation, the challenges of attracting LP capital…
Read MoreVenture capital is evolving, and so is biotech. In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of VibeBio, sits down with Alex Bangash, Founder of Transpose, an investment firm backing both startups and funds. With over 20 years of experience in venture investing, Alex shares his unconventional journey from engineering to investing and how his unique perspective has shaped his approach to funding.
Read MoreIn this special episode of Biotech 2050, Host Alok Tayi, CEO and Co-Founder of VibeBio, delves into the world of neurodivergent entrepreneurship and impact investing with guest Chad Belinsky, founder of AtypicalPath.org. Chad shares his inspiring journey from running a transformative B2B materials company to establishing Atypical Path—a nonprofit dedicated to supporting neurodiverse individuals, fostering mentorship, and creating impact-driven investment opportunities.
Read MoreIn this episode of Biotech 2050, host Alok Tayi explores the world of biotech venture capital with Narayan Chowdhury, Co-Founder of Franklin Park. As a key player in funding the next wave of biotech breakthroughs, Narayan shares how limited partners (LPs) navigate risk, identify high-potential biotech funds, and decide where to allocate billions in capital.
Read MoreJoin host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model and set the stage for a wave of life-changing innovations.
Read MoreHost Rahul Chaturvedi leads an insightful conversation with Dr. Kristin Yarema, President and CEO of Poseida Therapeutics. Kristin shares the inspiring journey of her career, from her roots in science to leadership roles in big pharma, culminating in her move to biotech entrepreneurship. She reflects on pivotal experiences at Novartis and Amgen, her deep-seated passion for oncology and autoimmune diseases, and the exciting leap into the field of cell therapy.
Read MoreIn this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company’s pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bharatt and Eric share their professional journeys and key insights, emphasizing the importance of simplicity and unwavering commitment to impactful ideas.
Read MoreRob Williamson, CEO of Triumvira, joins Biotech 2050 host, Rahul Chaturvedi, to discuss his dynamic career from economics to biotech, tackling the volatile capital markets, and navigating high-stakes decisions in cell therapy. He shares insights on therapeutic developments in cell therapy, the pressures of solid tumor research, and the evolving biotech ecosystem.
Read MoreBiotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, which targets Parkinson's disease by aiming for disease modification rather than symptom management.
Read MoreDiscover how Bitterroot Bio is poised to revolutionize cardiovascular health in this captivating conversation between host Rahul Chaturvedi and CEO Pavan Cheruvu. Pavan opens up about his inspiring journey from engineering to leading a biotech company at the forefront of cardio-immunology. Learn how his visionary leadership is driving innovative solutions to combat atherosclerosis—one of the world’s deadliest diseases.
Read More
